Differences between revisions 40 and 41
← Revision 40 as of 2006-11-17 21:19:37 →
Size: 6642
Editor: lfrq80
Comment: Removed duplicate entry
← Revision 41 as of 2006-11-20 15:29:07 →
Size: 7043
Editor: lfrq80
Comment: Added hooks for new use cases, added link to another reference article
Deletions are marked like this. Additions are marked like this.
Line 41: Line 41:
 * /BooleanLogic
Line 46: Line 47:
 * /DnaSite
Line 50: Line 52:
 * /ProductAppears
 * /ProteinBindingSites
Line 60: Line 64:
 * /TranscriptionInhibitionShorthand
 * /TranscriptionShorthand
Line 66: Line 72:
 * /PathHighlight
Line 70: Line 77:

A newer version of the description of the notation is found in Kohn et al
http://mct.aacrjournals.org/cgi/rapidpdf/1535-7163.MCT-06-0640v2
Line 99: Line 109:
 1. Do they need site-specific connection of edges, e.g. as in proteolytic cleavage? From Mirit's presentation, it appears that metanodes would work just fine.  1. Do they need site-specific connection of edges, e.g. as in proteolytic cleavage? From Mirit's presentation, it appears that metanodes would work just fine. ( see /ProteinBindingSites
and /ProteinDomains)
Line 101: Line 112:
 1. How do we represent the "null" node, as in degradation product?  1. How do we represent the "null" node, as in degradation product? (see /SpeciesDegradation)
Line 103: Line 114:
 1. How do we represent "ditto" nodes, e.g. as in translocation?  1. How do we represent "ditto" nodes, e.g. as in translocation? (see /ShowTransport)

Molecular Interaction Maps

Editor(s): Allan Kuchinsky

TableOfContents([2])

About this document

This is an official Request for Comment (RFC) for Supporting Molecular Interaction Maps in Cytoscape.

For details on RFCs in general, check out the [http://www.answers.com/main/ntquery?method=4&dsid=2222&dekey=Request+for+Comments&gwp=8&curtab=2222_1&linktext=Request%20for%20Comments Wikipedia Entry: Request for Comments (RFCs)]

Status

* preliminary draft, still brain-dead, take with a grain of NaCl.

How to Comment

To view/add comments, click on any of 'Comment' links below. By adding your ideas to the Wiki directly, we can more easily organize everyone's ideas, and keep clear records. Be sure to include today's date and your name for each comment. Here is an example to get things started: ["/Comment"].

Try to keep your comments as concrete and constructive as possible. For example, if you find a part of the RFC makes no sense, please say so, but don't stop there. Take the extra step and propose alternatives.

Proposal

A Molecular Interaction Map (MIM) is a diagram convention that is capable of unambiguous representation of networks containing multi-protein complexes, protein modifications, and enzymes that are substrates of other enzymes. MIMs are described in detail at http://discover.nci.nih.gov/mim/index.jsp and in a seminal article by Kohn et al at http://www.molbiolcell.org/cgi/content/abstract/E05-09-0824v1

An example MIM is below attachment:mim_eg.png

MIMs have been developed at the National Cancer Institute (specifically the Laboratory of Molecular Pharmacology). They are looking into what it would take to develop an Editor to create Molecular Interaction Maps (MIMs) in an editor to yield both a graphical view and a computer-readable format (preferrably BioPax). They are interested in seeing if such a MIM editor could be developed for Cytoscape.

MIM symbols are defined in the figure below:

attachment:Kohn_SymbDefH3.jpg

QUESTION: Is this the most recent definition of map symbols? In particular, are site-specific constructs, such as cleavage, still defined as requirements? ANSWER:There are a few changes. CovalentBinding has a new symbol. There are some requirements for site-specific constructs. There are a few additional symbols as well.

This proposal will specify the mapping between MIM constructs and their proposed counterparts in Cytoscape. A prioritized set of requirements will be presented. Enhancements needed in the editor, renderer, and/or other Cytoscape components will be identified.

Biological Questions / Use Cases

/MimEditorUseCaseComments

Kohn Notation Use Cases

Editor System Use Cases

General Notes

From an initial reading of the article by Kohn et al at http://www.molbiolcell.org/cgi/content/abstract/E05-09-0824v1, an initial description of potential mappings between MIM and Cytoscape constructs was derived. This is summarized in the figure below.

A newer version of the description of the notation is found in Kohn et al http://mct.aacrjournals.org/cgi/rapidpdf/1535-7163.MCT-06-0640v2

attachment:kohn_mappings.png

Further Notes from meeting at 2006 Cytoscape Developers Retreat

  • Need to map MIM to both model and view
    • How to represent 'non covalent binding'?
      • Model: Best mapped to a group. A and B are connected and are part of the group.
      • View: this is a use case for the group view
    • Asymmetric binding
      • Model: Regular edge between A and B, just needs a specific edge type
      • View: New type of custom edge graphic (will take some care with Nerius' edge drawing code)
    • Representation of multimolecular complexes
      • Model: A group of groups
      • View: part of the use case for group view
    • Covalent modification of protein A (post-translational modification = PTM)
      • Model: A is a node (representing unmodified protein); central node is a node (represented modified A) - every state is represented as a node. The PTM e.g. P is not a node, it is an annotation on the 'central' state node. The edge between A and its state is of type 'state of'. The set of all states is grouped to represent the set of all states of A.
      • View: Constraint: the states always move together (would be like a template)
    • Cleavage of of a covalent modification of protein A
      • Model: Hyperedge containing node1: Phtase (hyperedge attribute: enzyme), node2: phosphorylated A, node3: unphosphorylated A
      • View: Use case for hyperedge view
  • General constraints for automatic layout and the editor
    • Snap to grid
    • All lines need to be routed with only right or acute angles
    • Central node is only there if it is used (connected to something else in the diagram)
  • Next step: a special interest group should get together to hash the above out further. Current interested people are: Allan, Mirit, David, Gary, Aditya, Scooter, Alex; also general interest from Nathan, Kristina (GenMAPP editing), Ethan, Ben (BioPAX editing)
  • Implementation: Cytoscape core would ensure that the model and view requirements are met. Users: like GenMAPP, MIM, BioPAX editing would use the core functionality to create their own plugins that implemented their own pathway editing features.

Requirements

Deferred Items

Open Issues

  1. Do they need site-specific connection of edges, e.g. as in proteolytic cleavage? From Mirit's presentation, it appears that metanodes would work just fine. ( see /ProteinBindingSites

and /ProteinDomains)

  1. How do we represent the "null" node, as in degradation product? (see /SpeciesDegradation)

  2. How do we represent "ditto" nodes, e.g. as in translocation? (see /ShowTransport)

  3. Would they need editor support for Manhattan topology, e.g. constraints on edge angles?

Backward Compatibility

Expected growth and plan for growth

References

Implementation Plan

  • [:Molecular Interaction Maps/Implementation Plan:/Implementation Plan]

Comments

PageComment2

Molecular_Interaction_Maps (last edited 2009-02-12 01:03:29 by localhost)

Funding for Cytoscape is provided by a federal grant from the U.S. National Institute of General Medical Sciences (NIGMS) of the Na tional Institutes of Health (NIH) under award number GM070743-01. Corporate funding is provided through a contract from Unilever PLC.

MoinMoin Appliance - Powered by TurnKey Linux